From September 13, 2021 through April 24, 2022, the HHS Administration for Strategic Preparedness and Response (ASPR) used a state and territory-coordinated distribution system for COVID-19 therapeutics. The tables below are being made available for archival purposes only.
On April 25, HHS/ASPR transitioned to a new system based on established thresholds for each jurisdiction. To find out how HHS/ASPR is currently bringing COVID-19 therapeutics to your state or territory, see
COVID-19 Therapeutics Thresholds, Orders, and Replenishment by Jurisdiction.
Total COVID-19 Therapeutics Courses Made Available
September 13, 2021 - April 24, 2022
| Distribution Period |
REGEN-COV |
Bam/ete |
Sotrovimab |
Evusheld |
Paxlovid |
Lagevrio (molnupiravir) |
Bebtelovimab |
Total Courses Made Available |
|
Apr 18–Apr 24, 2022 |
0 |
0 |
0 |
0 |
175,000 |
99,960 |
30,000 |
304,960 |
|
Apr 11–Apr 17, 2022 |
0 |
0 |
0 |
0 |
175,000 |
99,960 |
30,000 |
304,960 |
|
Apr 4–Apr 10, 2022 |
0 |
0 |
16,608 |
199,992 |
175,000 |
99,984 |
30,000 |
521,584 |
|
Mar 28–Apr 3, 2022 |
0 |
0 |
29,778 |
0 |
175,280 |
99,960 |
30,000 |
335,018 |
|
Mar 21–Mar 27, 2022 |
0 |
0 |
33,102 |
0 |
175,000 |
99,984 |
28,345 |
336,431 |
|
Mar 14–Mar 20, 2022 |
0 |
0 |
52,248 |
0 |
175,000 |
174,960 |
49,000 |
451,208 |
|
Mar 7–Mar 13, 2022 |
0 |
0 |
52,242 |
199,992 |
175,000 |
174,960 |
49,000 |
651,194 |
|
Feb 28–Mar 6, 2022 |
0 |
0 |
46,986 |
49,992 |
0 |
0 |
51,990 |
148,968 |
|
Feb 21-27, 2022 |
0 |
0 |
52,194 |
49,992 |
148,980 |
349,776 |
49,000 |
649,942 |
|
Feb 14-20, 2022 |
0 |
0 |
52,248
|
49,992 |
0 |
0 |
48,745 |
150,985 |
|
Feb 7-13, 2022 |
0 |
0 |
52,248 |
49,264 |
99,940 |
399,840 |
n/a |
601,292 |
|
Jan 31-Feb 6, 2022 |
0 |
0 |
52,104 |
74,960 |
0 |
0 |
n/a |
127,064 |
|
Jan 24-30, 2022 |
0 |
0 |
52,260 |
74,976 |
99,980 |
399,980 |
n/a |
627,196 |
|
Jan 17-23, 2022 |
55,224 |
44,550 |
52,064 |
73,752 |
0 |
0 |
n/a |
225,590 |
|
Jan 10-16, 2022 |
55,324 |
44,880 |
52,128 |
74,664 |
99,960 |
399,920 |
n/a |
726,876 |
|
Jan 3-9, 2022 |
54,472 |
44,520 |
48,498 |
49,896 |
0 |
0 |
n/a |
197,386 |
|
Dec 27, 2021 |
56,454 |
45,660 |
49,552 |
50,664 |
0 |
0 |
n/a |
202,330 |
|
Dec 23, 2021 |
0 |
0 |
0 |
0 |
0 |
300,620 |
n/a |
300,620 |
|
Dec 22, 2021 |
0 |
0 |
0 |
0 |
64,970 |
0 |
n/a |
64,970 |
|
Dec 17, 2021 |
0 |
0 |
55,002 |
0 |
n/a |
n/a |
n/a |
55,002 |
|
Dec 17, 2021 |
0 |
0 |
0 |
50,208 |
n/a |
n/a |
n/a |
50,208 |
|
Dec 13-26, 2021 |
111,300 |
88,700 |
0 |
0 |
n/a |
n/a |
n/a |
200,000 |
|
Nov 29-Dec 12, 2021 |
111,492 |
90,100 |
0 |
n/a |
n/a |
n/a |
n/a |
201,592 |
|
Nov 15-28, 2021 |
88,692 |
52,474 |
35,166 |
n/a |
n/a |
n/a |
n/a |
176,332 |
|
Nov 8-14, 2021 |
50,004 |
30,010 |
20,016 |
n/a |
n/a |
n/a |
n/a |
100,030 |
|
Nov 1-7, 2021 |
63,154 |
37,740 |
25,062 |
n/a |
n/a |
n/a |
n/a |
125,956 |
|
Oct 25-31, 2021 |
76,044 |
45,530 |
30,330 |
n/a |
n/a |
n/a |
n/a |
151,904 |
|
Oct 18-24, 2021 |
89,208 |
45,400 |
27,072 |
n/a |
n/a |
n/a |
n/a |
161,680 |
|
Oct 11-17, 2021 |
64,656 |
77,010 |
42,234 |
n/a |
n/a |
n/a |
n/a |
183,900 |
|
Oct 4-10, 2021 |
124,272 |
66,370 |
n/a |
n/a |
n/a |
n/a |
n/a |
190,642 |
|
Sept 27-Oct 3, 2021 |
139,644 |
59,350 |
n/a |
n/a |
n/a |
n/a |
n/a |
198,994 |
|
Sept 21-26, 2021 |
139,304 |
60,208 |
n/a |
n/a |
n/a |
n/a |
n/a |
199,512 |
|
Sept 13-20, 2021 |
158,580 |
17,880 |
n/a |
n/a |
n/a |
n/a |
n/a |
176,460 |
Prior COVID-19 Therapeutic Product Efforts
| Date Range |
Threshold/Distribution/Allocation by Jurisdiction |
April 25, 2022 - April 30, 2023
|
COVID-19 Therapeutics Threshold Determinations
|
| November 9, 2020 - March 2, 2021 |
Bamlanivimab Distribution |
| November 24, 2020 - February 2, 2021 |
REGEN-COV Distribution |
| July 6, 2020 - October 4, 2020 |
Allocation of Commercial Veklury (Remdesivir) (PDF) |
May 4, 2020 - June 29, 2020
|
Allocation of Donated Veklury (Remdesivir)
|
